31-40 of 77 results
Competition news
In Touch looks at what's been happening in Competition this month and what it means for your business ...
Making sense of human cell and tissue products regulation
The Therapeutic Goods Administration has released guidance on recent changes to the regulation of human cell and tissue products Special Counsel Ric Morgan and Senior Associate Tracy Lu dissect the complex regulatory framework particularly in relation to advertising ...
Allens acts for Healthscope on Asian pathology sale
Allens has advised Healthscope Limited, one of Australia's leading private healthcare operators, on the sale of its Asian pathology operations in Singapore, Malaysia and Vietnam to funds managed by ...
Allens advises Clearskincare on $127.4m acquisition
Allens has advised the founders of Clearskincare on the sale of the brand's clinic and products businesses to Australian Pharmaceutical Industries (API) for $127.4 million. Under the deal, API will ...
Allens advises PEP on acquisition of LifeHealthcare
Allens has advised private equity fund manager Pacific Equity Partners (PEP) in relation to the acquisition of ASX-listed LifeHealthcare Group Limited (LifeHealthcare) by Pacific Health Supplies ...
ACCC's Enforcement and Compliance priorities for 2017
Criminal cartels unfair contract terms consumer guarantees and the health construction and agriculture sectors are some of the ACCCs key enforcement and compliance priorities for 2017 ACCC Chairman Rod Sims released the ACCCs 2017 Compliance and Enforcement Policy on Friday 24 February 2017 ...
Using third party brands in video games: issues and opportunities
One of the emerging battlegrounds for brand owners is video games, particularly with the growth of virtual reality applications. A recent claim made in the US illustrates how having your brand featured in a video game can be a problem - but depending on the circumstances, it could also present a com ...
Special Report: Understanding the opportunities and navigating the legal frameworks of distributed ledger technology and blockchain
Authored by a multidisciplinary team from Allens Blockchain Reaction is designed to assist business stakeholders decision makers and in-house counsel across a variety of sectors to understand the technology and how it is being used as well as navigate the regulatory and legal opportunities and ...
High Court unanimously finds isolated genetic material not patentable
In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...
Assessment of biosimilars - Is Australia leading, following or going its own way?
The ongoing lack of certainty about what is required to obtain biosimilar registration in Australia extends to three key issues - Comparability is the new product sufficiently similar to permit it to rely on the reference products safety and efficacy data Extrapolation for which of the indications ...